Cyramza for Non-Small Cell Lung Cancer - Details

Détails

Generic Name:

Ramucirumab

Fabricant:

Eli Lilly Canada Inc.

Brand Name:

Cyramza

Gamme de produits:

Examen en vue du remboursement

Tumour Type:

Lung

Indications:

Non-Small Cell Lung Cancer

Funding Request:

For the treatment of patients with advanced or metastatic non-small cell lung cancer who progressed on or after platinum-based chemotherapy in combination with docetaxel

Review Status:

Dossier fermé – Non présenté

Pre Noc Submission:

Yes

Date NOC Issued:

2 septembre 2016

Sponsor:

Eli Lilly Canada Inc.

Clarification:

The submitter notified pCODR that they will not be filing the submission.

Clarification:

The submitter notified pCODR that they were unable to submit by their original target date and an updated target submission date has been provided.

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Dernière mise à jour : 02 septembre 2016